SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
401 Professional Drive, Suite 260
Gaithersburg, MD 20879
August 8, 2025
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Trade & Services
100 F Street, N.E.
Washington, D.C. 20549
| Attention: | Mr. Tyler Howes |
| Re: | Shuttle Pharmaceuticals Holdings, Inc. | |
| Registration Statement on Form S-1 | ||
| Filed August 5, 2025 | ||
| File No. 333-289231 |
Dear Mr. Howes,
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Shuttle Pharmaceuticals Holdings, Inc. (the “Company”) respectfully requests that the Securities and Exchange Commission accelerate the effectiveness of the above-referenced Registration Statement on Form S-1 (the “Registration Statement”) and declare such Registration Statement effective at 4:30 p.m., Eastern Standard Time, on Monday, August 11, 2025, or as soon thereafter as practicable.
It would be appreciated if, as soon as the Registration Statement is declared effective, you would so inform Jeff Cahlon, Esq. of Sichenzia Ross Ference Carmel at 212-930-9700.
* * * *
Very Truly Yours,
| Shuttle Pharmaceuticals Holdings, Inc. | |
| /s/ Christopher Cooper | |
| Christopher Cooper | |
| Chief Executive Officer |
cc: Jeff Cahlon, Esq.